Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Dianthus Therapeutics (DNTH) Invested Capital (2017 - 2025)

Dianthus Therapeutics has reported Invested Capital over the past 8 years, most recently at $546.5 million for Q3 2025.

  • Quarterly results put Invested Capital at $546.5 million for Q3 2025, up 61.72% from a year ago — trailing twelve months through Sep 2025 was $546.5 million (up 61.72% YoY), and the annual figure for FY2024 was $352.5 million, up 108.73%.
  • Invested Capital for Q3 2025 was $546.5 million at Dianthus Therapeutics, up from $303.1 million in the prior quarter.
  • Over the last five years, Invested Capital for DNTH hit a ceiling of $546.5 million in Q3 2025 and a floor of -$61.5 million in Q2 2023.
  • Median Invested Capital over the past 4 years was $178.4 million (2023), compared with a mean of $180.4 million.
  • Biggest five-year swings in Invested Capital: tumbled 130.32% in 2023 and later skyrocketed 833.35% in 2024.
  • Dianthus Therapeutics' Invested Capital stood at -$44.4 million in 2022, then skyrocketed by 480.61% to $168.9 million in 2023, then soared by 108.73% to $352.5 million in 2024, then skyrocketed by 55.03% to $546.5 million in 2025.
  • The last three reported values for Invested Capital were $546.5 million (Q3 2025), $303.1 million (Q2 2025), and $328.6 million (Q1 2025) per Business Quant data.